Luye Pharma Group Ltd.

Quick facts

Marketed products

• INVEGA SUSTENNA

Phase 3 pipeline

• EU-Prolia · Bone metabolism / Osteoporosis
  EU-Prolia is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand) to reduce osteoclast formation and bone resorption.
• LY01005 · Oncology
  LY01005 is a small-molecule inhibitor that targets specific intracellular signaling pathways involved in cell proliferation and survival.
• LY01011 · Diabetes
  LY01011 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.
• LY03005 extended-release tablet · Psychiatry/Neurology
  LY03005 is a dopamine D2 receptor antagonist that blocks dopamine signaling in the central nervous system.
• LY06006
  LY06006 is a small-molecule inhibitor that targets specific intracellular signaling pathways involved in disease pathogenesis.
• LY09004 · Diabetes
  LY09004 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.
• Placebo, extended-release microspheres
  This drug is a placebo, meaning it has no active therapeutic effect.

Phase 2 pipeline

• LY01021
• LY03020

Phase 1 pipeline

• Irinotecan Hydrochloride Injection（CAMPTO®）
• LPM3480226
• LPM3770164 sustained release tablet
• LPM3770164 sustained release tablet simulant
• LPM6690176
• LY-CovMab
• LY010616
• LY03003
• LY03004
• LY03009 F1
• LY03009 F2
• LY03009 F3
• LY03009 F4
• LY03010
• LY03010; paliperidone palmitate
• LY03017
• LY03021
• Rotigotine, extended-release microspheres

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Luye Pharma Group Ltd. portfolio CI brief
• Luye Pharma Group Ltd. pipeline updates RSS